Evidence map›Paper›PMID 40733128›Full record

ArticlePharmaceutics2025

Synthesis and Evaluation of [

Guillermina Ferro-Flores, Myrna Luna-Gutiérrez, Blanca Ocampo-García, Nallely Jiménez-Mancilla, Nancy Lara-Almazán, Rigoberto Oros-Pantoja, Clara Santos-Cuevas, Erika Azorín-Vega, Laura Meléndez-Alafort

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guillermina Ferro-FloresDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares (ININ), Ocoyoacac 52750, Mexico.ORCID 0000-0003-0296-7605
Myrna Luna-GutiérrezDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares (ININ), Ocoyoacac 52750, Mexico.ORCID 0000-0002-4082-3816
Blanca Ocampo-GarcíaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares (ININ), Ocoyoacac 52750, Mexico.ORCID 0000-0002-5831-8412
Nallely Jiménez-MancillaInvestigadora por México SECIHTI, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-9480-4621
Nancy Lara-AlmazánDepartment of Nuclear Forensics and Analytical Chemistry, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-7491-0598
Rigoberto Oros-PantojaFaculty of Medicine, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.
Clara Santos-CuevasDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares (ININ), Ocoyoacac 52750, Mexico.ORCID 0000-0001-5903-1598
Erika Azorín-VegaDepartment of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares (ININ), Ocoyoacac 52750, Mexico.ORCID 0000-0002-7520-461X
Laura Meléndez-AlafortImmunology and Molecular Oncology Diagnostics Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0000-0003-0701-3616

Funding

Consejo Mexiquense de Ciencia y Tecnología" (COMECyT) through the program collaboration networks EDOMEX FICDTEM-2023-152International Atomic Energy Agency CRP-F22078Italian Ministry of Health 5 × 1000 (2019) "BRIDGE"project "DECURTA"
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

18F-iPD-L1iPD-L1 PET radiotracerPD-L1PD-L1 peptide inhibitors

Identifiers

PMID40733128
PMCPMC12298754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.